

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

# PCT

To:

see form PCT/ISA/220

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)

Date of mailing  
(day/month/year) see form PCT/ISA/210 (second sheet)

Applicant's or agent's file reference  
see form PCT/ISA/220

**FOR FURTHER ACTION**  
See paragraph 2 below

International application No.  
PCT/US2004/042377

International filing date (day/month/year)  
17.12.2004

Priority date (day/month/year)  
17.12.2003

International Patent Classification (IPC) or both national classification and IPC  
A61N1/39, A61N1/18

Applicant  
MEDTRONIC PHYSIO-CONTROL CORP.

### 1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

### 2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

### 3. For further details, see notes to Form PCT/ISA/220. :

Name and mailing address of the ISA:



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized Officer

Chopinaud, M

Telephone No. +49 89 2399-7365



**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

**10/583209**  
**IAP12 Rec'd PCT/PTO 16 JUN 2006**  
International application No.  
PCT/US2004/042377

---

**Box No. I Basis of the opinion**

---

1. With regard to the **language**, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
  - ☐ This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
  - a. type of material:
    - ☐ a sequence listing
    - ☐ table(s) related to the sequence listing
  - b. format of material:
    - ☐ in written format
    - ☐ in computer readable form
  - c. time of filing/furnishing:
    - ☐ contained in the international application as filed.
    - ☐ filed together with the international application in computer readable form.
    - ☐ furnished subsequently to this Authority for the purposes of search.
3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.  
PCT/US2004/042377

---

**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

---

1. Statement

|                               |             |      |
|-------------------------------|-------------|------|
| Novelty (N)                   | Yes: Claims |      |
|                               | No: Claims  | 1-34 |
| Inventive step (IS)           | Yes: Claims |      |
|                               | No: Claims  | 1-34 |
| Industrial applicability (IA) | Yes: Claims | 1-34 |
|                               | No: Claims  |      |

2. Citations and explanations

**see separate sheet**

Re Item V.

- 1 Reference is made to the following documents:

**D1 : US 3 865 101 A (SAPER ET AL) 11 February 1975 (1975-02-11)**

**D2 : US 2003/028219 A1 (POWERS DANIEL J ET AL) 6 February 2003 (2003-02-06)**

**D3 : US 5 105 821 A (REYES ET AL) 21 April 1992 (1992-04-21)**

- 2 INDEPENDENT CLAIM 1

The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of **claim 1 is not new** in the sense of Article 33(2) PCT.

Document D1 discloses (the references in parentheses applying to this document):

a **modular external defibrillator system** (system 10, figure 1), comprising :

a **base** (base 14, figure 1) containing a defibrillator to deliver a defibrillation shock to a patient;

**one or more pods** (pod 12, figure 1) each connectable to a patient via lead cables to collect patient data, the patient including at least one patient vital sign, the pods operable at a distance from the base; and

**a wireless communication link** (see figure 1 and description , column 2, lines 10-25) between the base and a selected one of the one or more pods to carry the patient data from the selected pod to the base, the selection being based on which pod is associated with the base.

- 3 The same reasoning applies to independent claim 23 for the same reason.
- 4 **Dependent claims 2-13 and claims 24-34** contain either features known per se from the prior art or being simple constructional features. Thus they would only satisfy Art. 33(2),(3) PCT when referring to a patentable independent claim.

5. In order to facilitate the examination of the conformity of the amended application with the requirements of Art. 34(2)(b) PCT, the applicant is requested to **clearly identify the amendments carried out**, no matter whether they concern amendments by addition, replacement or deletion, and to indicate the passages of the application as filed on which these amendments are based (see also Rule 66.8(a) PCT).

If the applicant regards it as appropriate these indications could be submitted in handwritten form on a copy of the relevant parts of the application as filed.